EGFR and glioblastoma: Analogously, mutations in the EGFR extracellular domain (ECD) are detected in patients with glioblastoma but are significantly less sensitive to EGFR TKIs in vitro compared to the EGFR kinase domain mutations found in lung cancer12, reinforcing the concept that not all mutations within a given gene can be therapeutically targeted in the same manner.